about
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsS1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder CancerPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairAtezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaCisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerErlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaDabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryLung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerEvaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy DosimetryAdj TC + Herceptin Early Stage Breast CancerA Study of Intravenous XMT-1001 in Patients With Advanced Solid TumorsA Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapyA Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsPARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsA Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic AdenocarcinomaStudy of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like TherapyStudy Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PROVelcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneRuxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid LeukemiaChemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerGemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersA Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHAA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerAn Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBCStudy of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate CancerA Multiple Myeloma Trial in Patients With Bone MetastasesGemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate CancerFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentDOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck CancerA Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung CancerPazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryTestosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor TreatmentA Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaStudy of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
P6153
Q58407779-398F3BC2-021D-4FB9-AB7F-0DD44E975014Q58407874-B2966697-BB36-4BC4-834A-213E17824F3EQ58845627-AEC7769A-AE53-4AFA-908B-AEF5F6E3C1ADQ58845885-FF5107D4-239C-4B0E-86D8-0458E083AC07Q58846476-77529A03-4849-47FB-BF75-70B690994098Q58846742-F9CA48FE-4F04-4D92-A013-2E1225E55908Q61713087-E37141C1-5015-44B1-AF40-13DF2FE55D54Q61862239-69A6B133-114F-4891-A42E-A9731D88ADDFQ61864729-C56C2BC1-8AA6-48C4-84AA-6E43286A6FF8Q61865593-A142B022-54E8-43ED-9792-1C9D78A5435BQ61906994-0D1D0B1F-304C-4919-A30E-83FDDF9E5811Q61914606-6BBACD8A-260C-4098-BD0E-38596DC76354Q61917781-3633C652-FDF4-4FEE-8D7B-55783AFD3BDAQ61920661-2B074B63-7FB4-47C1-8872-CC822C7C4CA6Q61921291-FE03D2AF-8604-43CA-9BA8-53058678015BQ61932385-F4D3D236-C557-412F-9970-56E80447BAE3Q61932780-40905D38-E09E-434B-8D00-F4B3B12D31B8Q61938289-8CAAE845-8349-4499-ABCA-F26AC9507134Q61955476-7A3A47A0-1C88-423D-BC6D-529099E03002Q61956233-C377BC69-0638-4E79-84C2-524A18D1181FQ61956506-207E0507-D4B4-43D4-BB50-08ABC22C4CE3Q61979804-65A99714-340A-4A85-BAD4-4ABC7037D303Q62025050-410D81DE-A963-4DB2-B83B-A5680865724DQ62030911-3818A4BD-F689-4621-9359-2DC563E5EA15Q62031551-D5F41530-B1E1-4012-A7A9-1D56CBFF8DF4Q62031862-1EAF8E93-CA9F-4F78-BC52-0B3E93AF502FQ62034171-D2771F9A-D509-4FC7-8DD9-A542B372EB40Q62054189-570F33C8-FB8A-4089-A727-C9715878FE14Q62062312-54441FB0-E712-4772-B0B4-56EB733C9452Q62105125-C1F2CEEC-661D-4986-A67B-BE78E79A4A1AQ62105903-29037136-0374-4647-B90E-C0A944360B19Q62110359-CD81E289-5B3B-404F-9D76-527E6EF1237EQ62811412-BD5C921F-17EE-40D9-8CBE-B2DF69D59B14Q62817334-12075160-7317-46A8-B815-E533686B24A8Q63011010-4AA4818A-14E2-486D-BCF5-5CD0B026DF81Q63063081-5BD3BAB6-3FA8-4548-A1DC-C4EF8736DAC2Q63315791-280E5737-E917-4015-95F0-E47FEE3B91A2Q63316114-210E93C3-91EB-44F6-AAE0-A2D7D904585DQ63322052-56B04EE4-4084-4489-93E2-4E371EB58A15Q63322078-87B42997-47A7-4EE1-BF7A-FF9962081D17
P6153
description
US-amerikanische Organisation
@de
organisatie uit Verenigde Staten van Amerika
@nl
other organization in Las Vegas, United States
@en
منظمة في لاس فيغاس، الولايات المتحدة
@ar
name
Comprehensive Cancer Centers of Nevada
@en
type
label
Comprehensive Cancer Centers of Nevada
@en
prefLabel
Comprehensive Cancer Centers of Nevada
@en
P131
P2427
grid.428254.d